Calif. stem cell grant raises concerns

Public interest groups criticize decision to award CHA Regenerative Medicine Institute nearly $3 million

Written byKirsten Weir
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
Two public interest groups are raising questions about the recipient of a $2.6 million grant awarded by California's stem cell agency. The watchdog groups have criticized the decision by the California Institute for Regenerative Medicine to pledge funding to the CHA Regenerative Medicine Institute (CHA RMI) of Los Angeles, citing numerous "red flags" about the organization and its affiliates.According to CIRM spokesperson Dale A. Carlson, the grantees have so far been evaluated purely on scientific merit, and CIRM won't distribute any money until staff members complete an administrative review of each application to verify the details of their affiliations, budgets, and medical and ethical standards. No checks will be cut "until we're satisfied that each institution and each investigator is capable of living up to our standards," said Carlson, who declined to speak specifically about the grant in question.This month, CIRM announced the winners of 29 comprehensive research grants worth $74.6 million, on top of $45 million worth of grants awarded in February. Principal investigator Jang-Won Lee of CHA RMI will receive $2.6 million to establish human embryonic stem cells by somatic cell nuclear transfer, using frozen eggs and somatic cells from patients with amyotrophic lateral sclerosis (Lou Gehrig's disease). The two agencies criticizing CIRM's decision, Center for Genetics and Society (CGS) and the Foundation for Taxpayer and Consumer Rights (FTCR), support embryonic stem cell research, but have been vocal critics of the California stem cell agency.Only academic and non-profit institutions in the state of California were eligible for this round of grants. CHA RMI is a non-profit research center, but FTCR stem cell director John M. Simpson has charged that the organization's relationship with for-profit Korean parent company CHA Health Systems may render CHA RMI ineligible. Of further concern, Simpson noted, CHA Health Systems chief executive Kwang Yul Cha has come under fire recently as a co-author on a scientific paper that was essentially identical to one published in a Korean journal. Cha was also a co-author on a controversial paper that showed prayer boosted the success of in vitro fertilization. "There are enough red flags that this warrants a closer look," Simpson told The Scientist.According to a statement released by CHA RMI, the organization was incorporated in California in 2005 and "has been engaged in adult and embryonic stem cell research at its Los Angeles laboratory...None of the member companies belonging to CHA Health Systems have any ownership interest in CHA RMI and none of the companies have any voting rights on CHA RMI's Board." According to the statement, Jang-Won Lee earned his PhD from the University of Connecticut and has held positions at Wake Forest Institute for Regenerative Medicine and Children's Hospital & Harvard Medical School. Lee could not be reached for comment.Stuart Orkin, an oncologist at Dana Farber Cancer Institute and chairman of the grants review committee, told The Scientist that he couldn't comment on the details of Lee's application. But in a public summary of the proposal, the reviewers noted that the "research plan is nicely developed" and the proposal "includes preliminary data in pigs" which "adds strength to the plan." The reviewers also noted a "large collection of letters of support." The reviewers' primary criticism was that the proposal was "overly ambitious." Renee Reijo-Pera, co-director of the University of California San Francisco's Human Embryonic Stem Cell Research Center and a recipient of a $2.5 million CIRM grant, told The Scientist that the CIRM application process is "so much more transparent than standard grant applications," including that of the NIH. "We have a process, it's very thorough, and we're following it," said Carlson. "We're doing our best to fund the very best science we can find."Kirsten Weir mail@the-scientist.comLinks within this article:California Institute for Regenerative Medicine http://www.cirm.ca.gov/A. McCook: "Blog: Calif. funds stem cell research - really," The Scientist, February 19, 2007. http://www.the-scientist.com/blog/display/52856/Center for Genetics and Society http://www.genetics-and-society.org/Foundation for Taxpayer and Consumer Rights http://www.consumerwatchdog.org/A. McCook: "Fertility journal censures scientists," The Scientist, February 20, 2007. http://www.the-scientist.com/news/display/52859A. McCook, "IVF-prayer study raises doubts," The Scientist, June 14 2004. http://www.the-scientist.com/article/display/22226Establishment Of Stem Cell Lines From Somatic Cell Nuclear Transfer-Embryos in Humans (Public Abstract) http://www.cirm.ca.gov/publicsummaries/rfa_06-02/summary/rc1-00123-1.htmlA. Holtz, "Stem cell disclosure resisted," The Scientist, August 22, 2006 http://www.the-scientist.com/news/display/24357Renee Reijo-Pera http://obgyn-nw.ucsf.edu/view_faculty.cfm?member=50
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform